What is the clinical value of adding tamoxifen to progestins in the treament of advanced or recurrent endometrial cancer?

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 1-3

  Herzog, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CISPLATIN; DOXORUBICIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDITORIAL; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RECURRENT CANCER; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE; WEIGHT GAIN;

EID: 0742290004     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.014     Document Type: Editorial

References (13)

1. Kelly R.M., Baker W.H. Progestational agents in the treatment of carcinoma of the endometrium. New Eng J Med. 264:1961;216-222.
2. Fiorica M., Brunetto V.L., Hanjani P.et al. Phase II trial of alternating course of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 91:2004;10-14.
3. Whitney C.W., Brunetto V.L., Zaino R.J.et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 91:2004;4-9.
4. Carlson JA, Allegra JC, Thomas GD, Jr, Wittliff J. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 149;149-53.
5. Satyaswaroop P.G., Zaino R.J., Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 44:1984;4006-4010.
6. Mortel R., Levy C., Wolff J.et al. Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestogen. Cancer Res. 41:1981;1140-1147.
7. Zaino R.J., Pondichery G., Satyaswaroop P.G., Mortel R. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model. Cancer Res. 45:1985;539-541.
8. Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 14:1996;357-361.
9. Thigpen J.T., Brady M.F., Alvarez R.D.et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 17:1999;1736-1744.
10. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 19:2001;364-367.
11. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S.et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 21:2003;3808-3813.
12. McMeekin D.S., Gordon A., Fowler J.et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 90:2003;64-69.
13. Bramlett K.S., Burris T.P. Target specificity of selective estrogen receptor modulators with human endometrial cancer cells. J Steroid Biochem Mol Biol. 86:2003;27-34.